CLINICAL_TRIALS ClinicalTrials.gov record update

A Multi-Institutional Phase I/II Study of Revlimid® (Lenalidomide), Velcade® (Bortezomib), Dexamethasone, and Doxil®, (RVDD) Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00724568
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:36:32.994594+00:00
Published At: 2014-09-10T00:00:00+00:00
Record Updated At: 2017-06-02
Results Posted At: 2014-09-10
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Multiple Myeloma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2017-06-02"
protocolSection.identificationModule.nctId: "NCT00724568"
protocolSection.identificationModule.officialTitle: "A Multi-Institutional Phase I/II Study of Revlimid\u00ae (Lenalidomide), Velcade\u00ae (Bortezomib), Dexamethasone, and Doxil\u00ae, (RVDD) Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2014-09-10"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.